Effect of diabetes mellitus on survival in patients with gallbladder Cancer: a systematic review and meta-analysis.
Diabetes mellitus
Gallbladder cancer
Meta-analysis
Mortality
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
24 Jul 2020
24 Jul 2020
Historique:
received:
17
12
2019
accepted:
06
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
7
2
2021
Statut:
epublish
Résumé
Increasing evidences indicated that diabetes might increase the incidence of gallbladder cancer. However, no sufficient data has ever clarified the impact of diabetes on the survival of patients with gallbladder cancer. We comprehensively searched PubMed, Embase, and the Cochrane Library databases through July 2019 in order to find sufficient eligible researches. The pooled hazard risks (HRs) and relative risks (RRs) with 95% confidence intervals (CIs) were calculated with either fix-effects or random-effects model. Due to the low gallbladder cancer mortality in general population, the RRs and standard mortality ratios (SMRs) were considered the similar estimates of the HRs. Ten eligible studies were included in this meta-analysis. Analysis of eight cohorts found that diabetes was closely associated with the mortality of gallbladder cancer (HR = 1.10; 95% CI: 1.06-1.14; P < 0.00001). However, the mortality in male diabetes patients was not higher than female patients (RR = 1.08, 95%CI = 0.57-2.04, P = 0.80). These findings indicated that diabetes patients had a higher mortality of gallbladder cancer compared with non-diabetes.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing evidences indicated that diabetes might increase the incidence of gallbladder cancer. However, no sufficient data has ever clarified the impact of diabetes on the survival of patients with gallbladder cancer.
METHODS
METHODS
We comprehensively searched PubMed, Embase, and the Cochrane Library databases through July 2019 in order to find sufficient eligible researches. The pooled hazard risks (HRs) and relative risks (RRs) with 95% confidence intervals (CIs) were calculated with either fix-effects or random-effects model. Due to the low gallbladder cancer mortality in general population, the RRs and standard mortality ratios (SMRs) were considered the similar estimates of the HRs.
RESULTS
RESULTS
Ten eligible studies were included in this meta-analysis. Analysis of eight cohorts found that diabetes was closely associated with the mortality of gallbladder cancer (HR = 1.10; 95% CI: 1.06-1.14; P < 0.00001). However, the mortality in male diabetes patients was not higher than female patients (RR = 1.08, 95%CI = 0.57-2.04, P = 0.80).
CONCLUSIONS
CONCLUSIONS
These findings indicated that diabetes patients had a higher mortality of gallbladder cancer compared with non-diabetes.
Identifiants
pubmed: 32709224
doi: 10.1186/s12885-020-07139-y
pii: 10.1186/s12885-020-07139-y
pmc: PMC7379826
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
689Références
Int J Cancer. 2007 Aug 15;121(4):856-62
pubmed: 17397032
Arch Surg. 2009 May;144(5):441-7; discussion 447
pubmed: 19451486
Ann Oncol. 2011 Mar;22(3):730-738
pubmed: 20705912
Popul Health Manag. 2020 Feb 3;:
pubmed: 32013762
Int J Cancer. 2012 Apr 1;130(7):1639-48
pubmed: 21544812
Clin Epidemiol. 2014 Mar 07;6:99-109
pubmed: 24634588
Diabetes Metab Res Rev. 2016 Jan;32(1):63-72
pubmed: 26111736
Blood. 2012 May 24;119(21):4845-50
pubmed: 22496152
Surg Clin North Am. 2014 Apr;94(2):343-60
pubmed: 24679425
Cancer Res. 2009 Sep 1;69(17):6857-64
pubmed: 19706757
World J Gastroenterol. 2005 Mar 21;11(11):1653-7
pubmed: 15786544
Proc Nutr Soc. 1990 Oct;49(3):451-8
pubmed: 1964219
Br J Cancer. 2007 Dec 3;97(11):1577-82
pubmed: 18000509
J Surg Oncol. 2008 Dec 1;98(7):485-9
pubmed: 18802958
Ann Med. 2009;41(5):371-9
pubmed: 19191082
Br J Cancer. 2005 Jun 6;92(11):2070-5
pubmed: 15886700
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Am J Pathol. 2006 Sep;169(3):877-88
pubmed: 16936263
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1127-35
pubmed: 21934509
Diabetes Care. 2012 Feb;35(2):299-304
pubmed: 22266734
Am J Epidemiol. 2004 Jun 15;159(12):1160-7
pubmed: 15191933
Diabetes Care. 2012 Sep;35(9):1835-44
pubmed: 22699290
Eur J Epidemiol. 2011 Nov;26(11):863-76
pubmed: 21938478
PLoS One. 2013;8(2):e56662
pubmed: 23437204
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Proc Nutr Soc. 2008 Aug;67(3):253-6
pubmed: 18452640
Diabetes Res Clin Pract. 2010 Sep;89(3):309-19
pubmed: 20493574
World J Gastroenterol. 2005 Oct 21;11(39):6182-7
pubmed: 16273647
Aliment Pharmacol Ther. 2000 May;14 Suppl 2:62-5
pubmed: 10903007
Cancer Causes Control. 2012 Feb;23(2):263-72
pubmed: 22094992
Medicine (Baltimore). 2015 Jul;94(26):e1055
pubmed: 26131819
Cancer Sci. 2004 Aug;95(8):674-8
pubmed: 15298731
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
Eur J Cancer. 2011 Mar;47(4):592-9
pubmed: 21067913
Diabetes Care. 2015 Feb;38(2):264-70
pubmed: 25488912
Eur J Cancer. 2013 Jul;49(10):2411-23
pubmed: 23562551
Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):76-81
pubmed: 18234643
BMC Cancer. 2013 Jun 26;13:310
pubmed: 23803148
Diabetologia. 2017 Jun;60(6):1022-1032
pubmed: 28265721
Int J Gynecol Cancer. 2013 Mar;23(3):402-12
pubmed: 23354371
Endocr Res. 2015;40(1):54-61
pubmed: 25105463
Radiographics. 2001 Mar-Apr;21(2):295-314; questionnaire, 549-55
pubmed: 11259693
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14763-8
pubmed: 20679224
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
pubmed: 11573044
J Diabetes Complications. 2016 Mar;30(2):368-73
pubmed: 26684168